Racial Differences Do Not Affect PSA Response With Lutetium Lu-177 Vipivotide Tetraxetan in mCRPC | OncLive PSA50 outcomes with lutetium Lu-177 vipivotide tetraxetan did not differ by race in patients with mCRPC.

PSA50 outcomes with lutetium Lu-177 vipivotide tetraxetan did not differ by race in patients with mCRPC, according to data from retrospective cohort study presented during @ascocancer.bsky.social #GU26 #oncology #pcsm #prostatecancer
Read more here: www.onclive.com/view/racial-...

Thank you to Maha H. Hussain, MD, FACP, FASCO, of @nufeinbergmss.bsky.social for presenting on treatment intensification in mHSPC! Stay tuned to onclive.com for all of our coverage of the 19th Annual NY GU Cancers Congress! #oncology #pcsm #ProstateCancer

PSA Response, PSMA Tumor Volume Are Not Aligned in Enzalutamide-Treated, Biochemically Recurrent Prostate Cancer | OncLive PSA decline or control was not found to be concordant with PSMA tumor volume changes among enzalutamide-treated patients with BCR prostate cancer.

📊New data suggest PSA response and PSMA-PET tumor volume don’t always align in patients with biochemically recurrent prostate cancer treated with enzalutamide—raising questions about how imaging should guide treatment decisions. #oncology #GU26 #pcsm
Read more here: www.onclive.com/view/psa-res...

Dr. Scott Tyldesley of UBC reports on 15-year ASCENDE-RT data: Brachytherapy boost halves PC-specific mortality (8.6% vs 16.4%, P=.007) but shows no OS benefit.

Read more here: ➡️ https://bit.ly/3OGoIaH

#pcsm #prostatecancer #ASCOGU26 #GU26

Alicia Morgans, MD, MPH, of @danafarber.bsky.social discusses data from a real-world analysis of androgen pathway receptor triplet regimens in mHSPC that were presented during the 2026 Genitourinary Cancers Symposium. #GU26 #prostatecancer #pcsm

Niraparib and Abiraterone Acetate Nets European Approval in BRCA1/2-Mutated mHSPC | OncLive The EC approved an indication extension for niraparib and abiraterone acetate dual action tablets plus prednisone/prednisolone with ADT in BRCA1/2-mutated mHSPC.

The European indication for niraparib and abiraterone acetate has expanded, with the EC approving the dual action tablets in combination with prednisone/prednisolone and ADT for BRCA1/2-mutated mHSPC #pcsm #oncology www.onclive.com/view/nirapar...

During our #GrandRounds, Dr. Daniel Petrylak was hailed as the ‘Father of Chemotherapy’ for #prostatecancer and shared his excitement for the future: "RIPTACs and bispecifics are incredibly promising, especially when combined with advancements in molecular sequencing." #pcsm
➡️ bit.ly/4rSHOsM

Dr Picozzi on the Significance of the PANOVA-3 Study for Future TTField Development in Pancreatic Cancer | OncLive Vincent Picozzi, MD, discusses how data from the phase 3 PANOVA-3 trial are foundational for the evaluation of Optune Pax with other immunotherapies.

📹Watch: Vincent Picozzi, MD, discusses how data from the phase 3 PANOVA-3 trial are foundational for the evaluation of Optune Pax with other immunotherapies in pancreatic cancer. #oncology #medtwitter #pcsm
👉Watch the full video here: www.onclive.com/view/dr-pico...

Experts Recount the Most Notable Data From the 2026 Genitourinary Cancers Symposium | OncLive OncLive spoke with experts in the field of GU oncology to gain perspective on the biggest presentations from the 2026 Genitourinary Cancers Symposium.

🧬 Experts unpack practice-shaping data in RCC, urothelial, & prostate cancer from the 2026 Genitourinary Cancers Symposium — including updates on LITESPARK-022, KEYNOTE-B15, SunRISE-2 & PEACE-3 📊
#GU26 #oncology #medtwitter #kcsm #pcsm
Check it out 👉 www.onclive.com/view/experts...

ERAS-Based Nursing Care Protocol Improved Outcomes After Laparoscopic Prostatectomy - Oncology Nurse Advisor This study investigated the outcomes of perioperative multidisciplinary nursing collaboration for patients who underwent laparoscopic radical prostatectomy.

Nurse-led ERAS protocols for LRP significantly improve recovery. Data show reduced incontinence (32.5% vs 56.5%, P<.001) and shorter hospital stays (5.2 vs 6.1 days). 🩺

From @frontiersin.bsky.social. Read the review: https://bit.ly/4aOgfuR

#MedEd #ProstateCancer #Nursing #pcsm

Thanks to David R. Wise, MD, PhD, of @nyulangone.bsky.social for dropping by for an interview to discuss findings from a phase 1b study of pasritamig plus docetaxel in metastatic castration-resistant prostate cancer. Check out hubs.li/Q045565l0 for all of our coverage of #GU26 #oncology #pcsm

Thank you to Ravi Madan, MD, for stopping by for an interview to discuss a study of enzalutamide monotherapy in biochemically recurrent prostate cancer! Stay tuned to onclive.com for highlights from the interview @ascocancer.bsky.social #GU26 #oncology #pcsm

Cabazitaxel Plus ADT/Radiotherapy Fails to Show Long-Term Survival Benefit in High-Risk Localized Prostate Cancer | OncLive Adding cabazitaxel to ADT and radiotherapy did not improve PFS or MFS vs SOC after 7 years among patients with high-risk localized prostate cancer.

Cabazitaxel Plus ADT/Radiotherapy Fails to Show Long-Term Survival Benefit in High-Risk Localized Prostate Cancer
@ascocancer.bsky.social #GU26 #pcsm www.onclive.com/view/cabazit...

Dr Bryce on the Implications of the Full FDA Approval of Rucaparib in BRCA+ mCRPC | OncLive Alan H. Bryce, MD, discusses the implications of the FDA’s full approval of rucaparib for BRCA mutation–associated mCRPC.

WATCH: Alan H. Bryce, MD, of @cityofhope.bsky.social, discusses the significance of the FDA’s regular approval of rucaparib for the treatment of BRCA mutation–associated mCRPC previously treated with an AR-directed therapy #pcsm #oncology

www.onclive.com/view/dr-bryc...

Lutetium Lu 177 Vipivotide Tetraxetan Plus ADT and an ARPI Maintains QOL in mHSPC | OncLive Lutetium Lu 177 vipivotide tetraxetan–based therapy generated similar QOL outcomes compared with ADT plus an ARPI alone in patients with mHSPC.

Lutetium Lu 177 Vipivotide Tetraxetan Plus ADT and an ARPI Maintains QOL in mHSPC @mskcancercenter.bsky.social @ascocancer.bsky.social #GU26 #pcsm #oncology
www.onclive.com/view/lutetiu...

Capivasertib Added to Abiraterone Extends rPFS in PTEN-Deficient mHSPC | OncLive The addition of capivasertib to abiraterone elicited an rPFS advantage and preserved QOL compared with placebo plus abiraterone in PTEN-deficient mHSPC.

Capivasertib Added to Abiraterone Extends rPFS in PTEN-Deficient mHSPC @dukecancer.bsky.social @ascocancer.bsky.social #GU26 #pcsm #oncology
www.onclive.com/view/capivas...

Figure of functional change after treatment, between open RP and 2-D RT. https://www.nejm.org/doi/full/10.1056/NEJMoa1209978

#ASCO #GU26
Session on localized #ProstateCancer
Dr. Ron Chen highlights functional impacts, comparing RP v RT
*Emphasizes for PCOS that was much less sophisticated radiation

I would add that was much less sophisticated surgery (open RRP) #pcsm

Find a Prostate Cancer Screening | Relax, It’s a Blood Test The first step in prostate cancer screening could be a simple blood test. Learn more about prostate cancer risk factors and find a screening site near you.

#ASCO #GU26
Re: comment from the audience:
I appreciate the patient advocate sharing he has a new #prostatecancer diagnosis stemming from his getting a #PSA spurred by the Super Bowl Ad!
#ScreeningSavesLives

www.relaxitsabloodtest.com?site=GK10010...
#pcsm

Novel Cooled Focal Therapy Achieves Short-Term Localized Prostate Cancer Control - Oncology Nurse Advisor The phase 2 ProFocal Laser Therapy for Prostate Tissue Ablation (PFLT-PC) trial tested a cooled laser focal therapy device for intermediate-risk prostate cancer treatment.

Phase 2: Cooled focal therapy shows 88% success in #prostatecancer at 12 mo. 🔬

• No urinary incontinence 📊
• 100% potency retention
• High QoL profile

Via @bjuijournal.bsky.social @renalurologynews.bsky.social.

Read more: https://bit.ly/4cB2rF9

#GUsm #MedEd #Oncology #pcsm

Dr Bilen on Real-World OS Benefit With Apalutamide vs Darolutamide in mCSPC | OncLive Mehmet Bilen, MD, discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.

WATCH 👀: Mehmet Bilen, MD, of @winshipcancer.emory.edu discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here 📽️: www.onclive.com/view/dr-bile...
#oncology #pcsm #mcspc

Dr Bilen on a Real-World Analysis of Apalutamide vs Darolutamide in mCSPC | OncLive Mehmet Bilen, MD, discusses the rationale for a real-world analysis of apalutamide vs darolutamide in mCSPC.

WATCH 👀: Mehmet Bilen, MD, of @winshipcancer.emory.edu discusses a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here ➡️: www.onclive.com/view/dr-bile...
#oncology #medtwitter #prostatecancer #pcsm #mcspc

Real-World Analysis Establishes OS Advantage With Apalutamide Plus ADT vs Darolutamide in mCSPC | OncLive Mehmet Bilen, MD, discusses a retrospective analysis of patients receiving apalutamide vs darolutamide for metastatic castration-sensitive prostate cancer.

Real-World Analysis Establishes OS Advantage With Apalutamide Plus ADT vs Darolutamide in mCSPC @emoryuniversity.bsky.social @winshipcancer.emory.edu #pcsm #oncology
www.onclive.com/view/real-wo...

#ProstateCancer often has a "cold" tumor microenvironment. A novel autovaccine aims to "reawaken" the immune response via patient-specific antigens. 🩺

Via @renalurologynews.bsky.social: • High specificity • Low toxicity

Read: https://bit.ly/4rgohC2

#pcsm #oncology #immunotherapy

Cribriform Prostate Cancer Has Higher Risk of Metastasis, Might Benefit From RT - Oncology Nurse Advisor Using PROTECT trial data, investigators assessed the possible benefit of early treatment vs active monitoring for cribriform-positive prostate cancer.

#Prostatecancer metastasis risk is increased for men with vs without cribriform morphology, investigators report. Research from Nikita Sushentsev, MD. Article from @renalurologynews.bsky.social.

https://bit.ly/4t7eEXV

#pcsm

Docetaxel rechallenge improved overall survival compared with switching to cabazitaxel, for patients with chemonaïve #mCRPC who did not experience progression during prior treatment with docetaxel. From @jamanetworkopen.com.

Read more here: ➡️ https://bit.ly/3NGNEyj

#prostatecancer #pcsm

Some Widely Consumed Food Preservatives Increase Cancer Risk, Research Suggests In this analysis, researchers aimed to investigate associations between preservative intake and cancer incidence in a large prospective cohort.

The consumption of a number of widely used food #preservatives is linked to an increased risk of overall, breast, and prostate #cancers. Published in @bmj.com.

https://bit.ly/3NmnUHw

#CancerRisk #bcsm #pcsm

Metastatic Prostate Cancer With Low-Volume Primary Tumors Has Poor Prognosis In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary tumors.

#Prostatecancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis.

https://bit.ly/49vP8nF

#pcsm #gucsm

The administration of leuprorelin acetate after radical #prostatectomy does not provide survival benefits in patients with nonmetastatic, high-risk #prostatecancer who have undetectable prostate-specific antigen levels. Reported in @eururoloncol.bsky.social.

https://bit.ly/4sHEEJw

#pcsm

Predicting Prostate Cancer Recurrence Through Power of AI | OncLive Mayo Clinic’s Department of Radiation Oncology has developed an AI monitoring tool to support clinicians in monitoring for prostate cancer recurrence.

Predicting Prostate Cancer Recurrence Through Power of AI @mayocliniccancer.bsky.social #oncology #pcsm #AI
www.onclive.com/view/predict...

Researchers Uncover How a Key Oncogene Drives Prostate Cancer at Its Earliest Stage | OncLive Researchers discovered that the oncogene ERG triggers cancer by reprogramming prostate basal cells.

Researchers Uncover How a Key Oncogene Drives Prostate Cancer at Its Earliest Stage @foxchasecancer.bsky.social #oncology #pcsm #prostatecancer
www.onclive.com/view/researc...